Table 3B.
Cox proportional hazards models for progression-free survival (PFS) and overall survival (OS) in all patients with non-small cell lung cancer excluding PD-L1 status, according to univariate (A) and multivariate (B) analyses.
| Items | PFS (Multivariate Analysis) a | OS (Mulitivariate Analysis) a | ||
|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| With irAEs | 0.53 (0.29-0.97) | 0.041 | ||
| With mild irAEs | 0.41 (0.22-0.77) | 0.005 | 0.32 (0.12-0.82) | 0.018 |
a
Covariables included sex (male vs female), age (≥ 70 vs < 70), histology (Squamous vs others), regimen (pembrolizumab vs atezolizumab), and brain metastasis.
Mild irAEs: showing in grade 1-2 irAEs. irAE: immune-related adverse event.